

1 VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY: Short Communication

2  
3 **Oral administration of bovine lactoferrin upregulates neutrophil**  
4 **functions in a dog with familial  $\beta$ 2-integrin-related neutrophil**  
5 **dysfunction**

6  
7  
8 Saori Kobayashi <sup>a</sup>, Yuya Abe <sup>a</sup>, Osamu Inanami <sup>b</sup>, Shinichi Oda <sup>c</sup>, Koji Yamauchi <sup>d</sup>,  
9 Careen Hankanga <sup>a</sup>, Jun Yasuda <sup>a</sup>, Reeko Sato <sup>a,\*</sup>

10 <sup>a</sup> *Laboratory of Veterinary Small Internal Medicine, Department of Veterinary Medicine,*  
11 *Faculty of Agriculture, Iwate University, 3-18-8 Ueda, Morioka 020-8550, Japan*

12 <sup>b</sup> *Laboratory of Radiation Biology, Department of Environmental Veterinary Medical*  
13 *Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Hokkaido,*  
14 *Kita 18 Nishi 9, Sapporo 060-0818, Japan*

15 <sup>c</sup> *Department of Animal Science, Faculty of Agriculture, Iwate University, 3-18-8 Ueda,*  
16 *Morioka 020-8550, Japan*

17 <sup>d</sup> *Food Science and Technology Institute, Morinaga Milk Industry Co., Ltd, 5-1-83*  
18 *Higashihara, Zama, Kanagawa 228-8583, Japan*

19  
20  
21  
22 \* Corresponding author. Tel. and fax: +81 19 621 6227.

23 *E-mail address:* reekos@iwate-u.ac.jp (Reeko Sato).  
24

24 **Abstract**

25 Lactoferrin, a glycoprotein present in neutrophils and exocrine secretions,  
26 plays important roles in host defense. Administration of bovine lactoferrin has been  
27 reported to modulate various neutrophil functions. We found a mixed-breed male dog  
28 with novel familial neutrophil dysfunction. The disorder was caused by a decrease of  
29  $\beta$ 2-integrin expression encoding CD18 without mutation. Antibiotics therapy alone  
30 didn't influence a series of neutrophil functions in the same dog. We examined the  
31 effects of oral administration of bovine lactoferrin on the neutrophil function and  
32 clinical symptoms in the same dog. Oral chronic administration of bovine lactoferrin  
33 increased neutrophilic  $\beta$ 2-integrin gene expression comparable to normal dogs, followed  
34 by the upregulation of surface CD18 expression. Concurrently, the superoxide  
35 production, phagocytic activity and adherence that were  $\beta$ 2-integrin-related neutrophil  
36 functions increased to normal canine levels. The chronic inflammation from bacterial  
37 upper respiratory infections and pneumonia was also alleviated in the dog. Our results  
38 indicate that oral treatment with bovine lactoferrin increases neutrophil  $\beta$ 2-integrin  
39 transcript level, leading to the upregulation of neutrophil functions and improvement of  
40 clinical symptoms in the dog with familial neutrophil dysfunction.

41 *Keywords:* bovine lactoferrin; integrins; CD11b/CD18; familial neutrophil  
42 dysfunction; superoxide production

43

## 43 1. Introduction

44 Neutrophils constitute the first line of host defense against microorganisms.  
45 Recurrent infections from a young age are associated with inherited neutrophil  
46 dysfunction. Congenital neutrophil dysfunction has been reported in dogs, for example,  
47 persistent neutropenia in border collies (Allan et al., 1996), canine leukocyte adhesion  
48 deficiency (CLAD) in Red and White Irish setters (Kijas et al., 1999) and  
49  $\beta$ 2-integrin-related neutrophil dysfunction in mixed-breed dogs (Kobayashi et al., 2009).  
50 The only definitive therapy is hematopoietic stem cell transplantation for chronic  
51 granulomatous disease (CGD), human and canine LAD (Bauer et al., 2005, Elhasid and  
52 Rowe, 2010, Seger, 2010). Recent successes in treating CLAD have demonstrated the  
53 therapeutic potential of stem cell gene therapy (Bauer et al, 2006 and 2007). However,  
54 these therapies have still some problems such as the need for a matched donor,  
55 transplant rejection and the risk of integration near oncogenes by virus receptors.  
56 Cytokines including granulocyte colony-stimulating factor (G-CSF) and IFN- $\gamma$  are also  
57 used as one of supportive treatments for CGD and congenital neutropenia (Roy-Ghanta  
58 et al., 2010). The cytokine therapy for long duration, however, has a risk of causing  
59 adverse effects. Especially, there are only a few products of homogenous cytokines used  
60 in veterinary medicine such as canine and feline IFN. Thus, the repeated treatment of  
61 anti-human cytokine, example for G-CSF, will stimulate the production of antibody  
62 against the heterologous protein in dogs and cats so that the use of G-CSF is limited for  
63 a short duration.

64 Lactoferrin, an 80 kDa iron-binding glycoprotein, is one of the primary host  
65 defense systems against infection. It is produced by neutrophils and exocrine glands,

66 and is present in neutrophil secondary granules and exocrine secretions (Ward et al.,  
67 2002). Its receptors have been found on neutrophils, mononuclear cells and  
68 brush-border cells (Spik et al., 1994). Synthesized CD11b/CD18 on neutrophils by  
69 stimuli triggered oscillations of cytosolic free  $\text{Ca}^{2+}$  followed by lactoferrin release and  
70 superoxide production in human neutrophils (Neuman et al., 1990, Richter et al., 1990,  
71 Suchard et al., 1994). Lactoferrin being released from activated neutrophils contributes  
72 to kill microorganisms, and regulates the cell counts and functions of neutrophils  
73 (Lönnerdal, and Iyer, 1995, Ward et al., 2005). It has also demonstrated that  
74 heterologous lactoferrin has anti-inflammatory and immunomodulatory activities  
75 (Kobayashi et al., 2005 and 2008, Yamada et al., 2008). Oral administration of bovine  
76 lactoferrin has shown to modulate phagocytic activity, superoxide production or  
77 adherence of peripheral neutrophils in healthy or feline immunodeficiency virus  
78 (FIV)-positive cats (Sato et al., 1996) and healthy volunteers (Yamauchi et al., 1998).  
79 Judging from these reports, administration of heterologous lactoferrin has sufficient  
80 potential to influence the performance of peripheral neutrophils.

81           Our previous study showed that the first recognized cases in mixed-breed  
82 dogs with familial neutrophil dysfunction (Kobayashi et al., 2009). The defect of  
83 neutrophil function was caused by downregulation of  $\beta 2$ -integrin transcript level  
84 without mutation. We examined the effects of oral chronic administration of bovine  
85 lactoferrin on the neutrophil function in one of the same dogs in this report.

86 **2. Materials and methods**

87

88 *2.1. Dogs*

89 Heparinized peripheral blood sample was obtained from a mixed-breed  
90 6-year-old male dog and eight healthy beagles (five males and two females, 2–6 years  
91 old). The healthy beagles were used as healthy controls for all neutrophil functions. The  
92 healthy dogs did not treat with any antibiotics.

93 The mixed-breed dog with familial neutrophil dysfunction was one of the same dogs  
94 that we reported previously (Kobayashi et al., 2009). Briefly, the mixed-breed  
95 littermates had suffered recurrent chronic bacterial infections from puppyhood, which  
96 was refractive to antibiotics or IFN- $\gamma$  therapy. At initial presentation to our Veterinary  
97 Teaching Hospital, the male dog had recurrent severe upper respiratory bacterial  
98 infections, oculo-nasal mucopurulent discharge, pneumonia and severe bilateral corneal  
99 opacity. The affected dog treated with antibiotics showed the disorders of neutrophil  
100 function.

101

102 *2.2. Oral administration of bovine lactoferrin*

103 Bovine lactoferrin (40mg/kg/day, twice a day) was administered orally with  
104 antibiotics for 140 days. It is a highly pure lyophilized powder derived from cow's milk.

105 The powder is light red-pink in color and virtually odorless and tasteless.

106

107 *2.3. Neutrophil functions*

108 Each measurement of neutrophil function was performed as described in our

109 previous report (Kobayashi et al., 2009). The healthy beagles were used as healthy  
110 controls for all neutrophil functions. The results of all neutrophil functions except  
111 superoxide production, phagocytic activity and adherence in the male dog with  
112 neutrophil dysfunction shown are representative of two independent experiments.  
113 Preliminary examination indicated that the oral administration with bovine lactoferrin  
114 for 28 days decreased slightly expression of CD18 and adherence, and increased slightly  
115 phagocytic activity and superoxide production in a healthy dog. All results were  
116 expressed as the mean value and min-max range in parentheses.

117

### 118 *2.3.1. Isolation of canine peripheral neutrophils*

119 Neutrophils ( $4.5-5.5 \times 10^6$  cells/ml) were isolated from 10 ml of blood using  
120 dextran sedimentation and Ficoll-conray density-gradient separation. The viability of  
121 isolated PMN was determined by 0.2% trypan blue staining (> 95%).

122

### 123 *2.3.2 Real-time reverse transcriptase polymerase chain reaction (RT-PCR) analysis*

124 Because the male dog with neutrophil dysfunction received antibiotics therapy  
125 had a low transcript level of CD11b and  $\beta$ 2-integrin, the real-time RT-PCR analysis was  
126 carried out with SYBR Green I as described in our previous report (Kobayashi et al.,  
127 2009). Briefly, total RNA from isolated neutrophils ( $5 \times 10^6$  cells) was extracted and  
128 was eluted in a final volume of 30  $\mu$ l RNase-free water. Spectrophotometer determined  
129 the high RNA yield and purity. The complementary deoxyribonucleic acid (cDNA) was  
130 synthesized from total RNA (0.17  $\mu$ g) of isolated neutrophils. Amplification of canine  
131 CD11b,  $\beta$ 2-integrin, lactoferrin and  $\beta$ -actin mRNA was performed by 1 cycle of 2 min at

132 50 °C, 10 min at 95 °C and 40 cycles of 15 s at 95 °C, 30 s at 62 °C, 40 s at 72 °C.  
133 Expression levels were quantified in duplicate by means of real-time RT-PCR. Cycle  
134 threshold values for genes of interest were normalized to  $\beta$ -actin and used to calculate  
135 the relative quantity of mRNA expression. The primer sequences used were described in  
136 our previous report (Kobayashi et al., 2009).

137

### 138 *2.3.3 Surface expression of adhesion molecules on leukocytes*

139 Because the male dog with neutrophil disorder showed a decrease in surface  
140 expression of CD11b/CD18 molecules, the expression of CD11b and CD18 was  
141 analyzed by a whole blood flow cytometric method as described in our previous report  
142 (Kobayashi et al., 2009). Briefly, after staining with FITC-labeled anti-CD11b and  
143 CD18, cells were resuspended in 0.5% paraformaldehyde in PBS. Analysis gate for  
144 neutrophils was expressed as mean fluorescence intensity (MFI) on a log-scale  
145 analyzing 10000 cells per sample as follows:  $MFI = (\text{Geo mean of target antibody} - \text{geo}$   
146  $\text{mean of negative control}) / \text{geo mean of negative control}$ .

147

### 148 *2.3.4. Neutrophil adherence*

149 Because the neutrophils in the male dog had abnormality through a mild  
150 decrease of adherence, neutrophil adherence to nylon fibers was examined according to  
151 the method of Nagahata et al. (1993). Total and differential neutrophil counts were  
152 performed before and after neutrophils suspension was allowed to percolate through the  
153 nylon fiber columns by gravity flow. Briefly, neutrophil suspension ( $5 \times 10^5$  cells)  
154 containing 10% autologous plasma was incubated for 10 min at 37 °C and then was

155 applied to a preincubated nylon wool fiber column. After percolating through the nylon  
156 fiber at room temperature, neutrophil counts were performed. Neutrophil adherence was  
157 calculated from the formula: percentage of neutrophil adherence =  $(1 - \text{counts of}$   
158  $\text{effluent neutrophil}/\text{counts of initial neutrophil}) \times 100$ .

159

#### 160 *2.3.5. Neutrophil phagocytic activity*

161 Because the neutrophils in the male dog showed a mild decrease of  
162 non-specific phagocytic activity, neutrophil phagocytic activity was measured by a  
163 whole blood flow cytometric method as described in our previous report (Kobayashi et  
164 al., 2009). Briefly, whole blood and non-opsonized microspheres were incubated for 30  
165 min at 37 °C and then PBS with 3 mM EDTA-2Na was added. After hemolysis, the cells  
166 were resuspended in 0.5% paraformaldehyde in PBS. Phagocytic activity expressed as  
167 percentage of the total neutrophil population ingesting fluorescent microspheres.

168

#### 169 *2.3.6. Neutrophil superoxide production*

170 The previous our study also showed that neutrophils from two littermates  
171 had a marked reduction in serum-opsonized zymosan (OZ)-stimulated superoxide  
172 production. The production of superoxide was measured by chemiluminescence with  
173 luminol as described in our previous report (Kobayashi et al., 2009) The  
174 chemiluminescence was measured with a luminometer (Luminescencer-PSN, ATTO Co.,  
175 Tokyo, Japan) at intervals of 2 s for total 30 min at 37 °C.

176

### 177 **3. Results and Discussion**



178 *3.1 The effect of bovine lactoferrin treatment on clinical findings*

179 At initial presentation to our Veterinary Teaching Hospital, the male dog with  
180 neutrophil dysfunction had recurrent severe respiratory bacterial infections as described  
181 in our previous report (Kobayashi et al., 2009). Despite symptomatic therapies such as  
182 fluid therapy, nebulization and administration of antibiotics for the first 2 weeks, clinical  
183 symptoms of the same dog did not improve. Twenty days after additional oral  
184 administration of bovine lactoferrin, oculo-nasal mucopurulent discharge appreciably  
185 decreased. And the symptoms of upper respiratory bacterial infections and bilateral  
186 corneal opacity were gradually improved. There was no difficulty in giving the dog  
187 lactoferrin. Finally, the dog stopped cough from pneumonia and was released from nasal  
188 obstruction 50-day lactoferrin treatment. And the dog had kept been in a comparative  
189 lull for the period of bovine lactoferrin administration. However, his owner failed to  
190 give the dog bovine lactoferrin for 2 weeks. The dog gradually developed bacterial  
191 upper respiratory infections. Bilateral oculo-nasal mucopurulent discharge was recurred  
192 on 140-day treatment after 14 day-suspension of lactoferrin. We also observed the  
193 recovery of clinical symptoms of upper respiratory bacterial infections in another  
194 female littermate with familial neutrophil dysfunction by oral treatment with bovine  
195 lactoferrin. The absorption and transportation kinetics of orally administered bovine  
196 lactoferrin still remain unclear. It has widely accepted that orally administered bovine  
197 lactoferrin is absorbed through the intestinal epithelium cells mediated by pathway of  
198 lactoferrin receptors, endocytosis or M cells in Peyer's patch. Takeuchi et al. (2004)  
199 demonstrated that intraduodenally administered bovine lactoferrin was transported into  
200 blood circulation via the thoracic duct lymph fluid in adult rats. This finding indicated

201 that the adult body could absorb orally administered heterologous lactoferrin. In  
202 addition, oral administration of bovine lactoferrin was reported to modulate functions of  
203 peripheral neutrophils in cats and human (Sato et al., 1996, Yamauchi et al., 1998).  
204 Therefore, it is possible that bovine lactoferrin and its derived peptides may be absorbed  
205 by the intestinal tract mucosal and influence the functions of peripheral blood  
206 neutrophils in the dogs with familial neutrophil dysfunction.

207

208 *3.2. The effect of bovine lactoferrin treatment on expression of neutrophil integrins and*  
209 *lactoferrin, and superoxide production*

210 Our previous study showed that antibiotics therapy didn't regulate all  
211 neutrophil functions of the male dog (Kobayashi et al., 2009). Real-time RT-PCR  
212 analysis revealed that low transcript levels of both CD11b and  $\beta$ 2-integrin in neutrophils  
213 from the same dog increased to the same levels as those of normal dogs after treatment  
214 of bovine lactoferrin (Fig. 1A). The CD11b mRNA level slightly increased from 0.64  
215 (0.39-0.95) to 1.06 (1.02-1.11) in the dog after 54-day bovine lactoferrin treatment  
216 [normal dogs, 0.84 (0.47-1.41), n=5]. Concurrently,  $\beta$ 2-integrin mRNA level  
217 upregulated profoundly from 0.09 (0.054-0.13) to 0.65 (0.52-0.78) in the affected dog  
218 after bovine lactoferrin treatment [normal dogs, 0.67 (0.42-0.93), n=5]. However, on  
219 day 140 after 14 day-suspension of bovine lactoferrin due to his owner's reasons, the  
220 dog showed decreases in CD11b and  $\beta$ 2-integrin mRNA expression to pretreatment  
221 level, 0.36 (0.30-0.43) and 0.09 (0.06-0.12), respectively. On the other hand, the dog  
222 that had normal lactoferrin transcript levels [0.43 (0.42-0.43) versus normal dogs, 0.43  
223 (0.27-0.56), n=5] showed a decrease of the lactoferrin level [0.29 (0.28-0.29)] after 140-

224 day treatment. The result indicates that heterologous lactoferrin may affect the secretion  
225 of endogenous lactoferrin. A study reported that  $\beta$ 2-integrin transcript level was  
226 downregulated by overexpression of PKC-zeta (Noti et al., 2001). However, the factors  
227 and mechanisms that regulate the transcript expression of  $\beta$ 2-integrin in neutrophils are  
228 not fully understood. We could not clarify the mechanism of positive modulation of  
229 transcript level of  $\beta$ 2-integrin by oral treatment with bovine lactoferrin in the dog. It  
230 might be possible that neutrophils of the dog may have a defect in transcriptional  
231 regulatory mechanism of  $\beta$ 2-integrin mRNA including intracellular signaling or in  
232 system of lactoferrin release. And bovine lactoferrin might compensate for the defect  
233 directly or indirectly. Further experiments will be required to examine the recoverable  
234 mechanism in oral treatment with bovine lactoferrin on neutrophil functions in the dog.

235 Cytometric analysis showed that chronic administration of bovine  
236 lactoferrin gradually increased the surface expression of CD18 but not CD11b in the  
237 dog (Fig. 1B). On 94-day treatment with bovine lactoferrin, the expression of CD18  
238 molecule was increased by about 146% of pretreatment level in the affected dog  
239 (pretreatment, 28.5%; 94 days, 41.72%). However, the expression level didn't increase  
240 to normal canine levels [67.41 (58.7-75.3) %, n=5]. On day 140 after 14 day-suspension  
241 of bovine lactoferrin, the dog showed a slight decrease in CD18 expression from  
242 41.72% to 40.75%. On the contrary, surface expression of CD11b was kept in a low  
243 level after bovine lactoferrin treatment [pretreatment, 2.88%; 94 days, 2.97%; 140 days,  
244 2.78%; normal dogs, 6.28 (5.78-7.64) %, n=5]. Noti et al. (2001) demonstrated that  
245 change of  $\beta$ 2-integrin transcript level resulted in modulation of membrane CD18  
246 expression on neutrophils. Our result suggested that  $\beta$ 2-integrin mRNA expression was

247 increased profoundly by oral administration of bovine lactoferrin and led to an increase  
248 of membrane CD18 expression. On the other hand, the slight increased the transcript  
249 level of CD11b by treatment with bovine lactoferrin did not result in an increase of  
250 membrane CD11b expression. The results suggested that increased expression of  
251 membrane integrin may require a significant increase in the gene expression.

252 The characteristic finding of the dog was a profound reduced response of the  
253 OZ-induced superoxide production (Kobayashi et al., 2009). Chronic oral  
254 administration of bovine lactoferrin resulted in a marked increase of superoxide  
255 production in the same dog (Fig. 2). The maximum amount of luminescence was  
256 increased by about 75% (79055/sec) and 72% (76966/sec) of normal canine level on  
257 14-day and 54-day treatment with bovine lactoferrin, respectively. Eventually, the  
258 superoxide production increased to the same level of healthy dogs completely after  
259 94-day treatment (114775/sec). However, suspension of bovine lactoferrin for 14 days  
260 led to a slight decrease of the maximum amount of luminescence to 106807/sec on day  
261 140. CD11b/CD18 blockade or  $\text{Ca}^{2+}$  chelators inhibited both lactoferrin release and  
262 superoxide production in human and mouse neutrophils (Nielsen et al., 1997, Mocsai e  
263 al., 2002). A recent study using lactoferrin-deficient mice with normal expression of  
264 CD18 showed that superoxide production was normal in response to stimulation with  
265 opsonized bacteria (Ward et al., 2008). Moreover, CD18-deficient neutrophils from  
266 LAD patients were shown to fail to release lactoferrin and produce superoxide in  
267 response to OZ or fMLP (Suchard et al., 1994, Bauer et al., 1998). These reports  
268 suggest that expression level of CD18 on neutrophils is major requirement for  
269 degranulation of lactoferrin and subsequent superoxide production in response to OZ in

270 neutrophils. In addition, our *in vitro* study showed that addition of bovine lactoferrin  
271 increased superoxide production in feline isolated neutrophils dose-dependently  
272 (unpublished data). It was also reported that oral administration of bovine lactoferrin  
273 showed a slight increase of neutrophilic phagocytic activity and superoxide production  
274 in cats and human (Sato et al., 1996, Yamauchi et al., 1998). Therefore, our results  
275 suggested that increased expression of CD18 by oral administration of bovine  
276 lactoferrin resulted in upregulation of OZ-induced superoxide production in the dog.

277

### 278 *3.3. The effect of bovine lactoferrin treatment on adherence and phagocytic activity*

279 Our previous report demonstrated that the dog's neutrophils exhibited  
280 reductions in  $\beta$ 2-integrin-related adherence and non-specific phagocytic activity  
281 (Kobayashi et al., 2009). As shown in Fig. 3A, the adherence increased to a normal  
282 canine level in the same dog after 7-day lactoferrin treatment [pretreatment, 19.30%; 7  
283 days, 35.41%; normal dogs, 31.74 (29.1-34.0) %, n=5]. Thereafter, adherence was  
284 decreased to 32.72% on 14 days and 26.5% on 94-day treatment, followed by a slight  
285 increase on 140-day treatment (29.6%). As shown in Fig. 3B, the low non-specific  
286 phagocytic activity (32.20%) increased to normal level on 14-day treatment [47.64%;  
287 normal dogs, 45.15 (43.3-48.6) %, n=5] and 58.35% on 94-day treatment. However, the  
288 activity on day 140 showed a slight decrease to 50.48% by suspension of bovine  
289 lactoferrin for 14 days. It was demonstrated that oral administration of bovine  
290 lactoferrin modulated neutrophilic phagocytic activity in cats and human, suggesting the  
291 involvement of expression of adhesion molecules (Sato et al., 1996, Yamauchi et al.,  
292 1998). Our results suggested one of the possible mechanisms by which adherence and

293 phagocytic activity through membrane integrins may be increased by an upregulation of  
294 membrane CD18 expression.

295 In conclusion, our all results suggest that the upregulation of  $\beta$ 2-integrin  
296 transcript level by treatment with bovine lactoferrin led to improve integrin-related  
297 neutrophil functions and clinical symptoms in the same dog in our previous study  
298 (Kobayashi et al., 2009). Therefore, our findings indicate that upregulation of  
299  $\beta$ 2-integrin expression is of key importance to restoration of neutrophil function in the  
300 case. In addition, suspension of bovine lactoferrin resulted in regression of the  
301 neutrophil functions in the dog. It seems likely that the dog with the disorders of  
302 neutrophil function and clinical symptoms in this report needs to take lifelong  
303 medication of bovine lactoferrin. Regarding long-term administration, bovine lactoferrin  
304 has been thought to be one of the dairy foods, because it has been detected in natural  
305 cheese and cheese whey, Moreover, 13-week oral repeated administration toxicity study  
306 showed that oral administration of bovine lactoferrin at high dose (2000 mg/kg/day) did  
307 not cause any adverse effects noted in the general condition of rats (Yamauchi et al.,  
308 2000). The observation suggests that heterologous bovine lactoferrin can be safe for  
309 chronic oral administration without allergy to lactoferrin. Oral administration with  
310 bovine lactoferrin may represent a therapeutic approach to the familial  
311  $\beta$ 2-integrin-related neutrophil dysfunction without  $\beta$ 2-integrin gene mutation.

312

### 313 **Acknowledgements**

314 This work was supported by MEXT KAKENHI 22780277.

315 **References**

- 316 Allan, F.J., Thompson, K.G., Jones, B.R., Burbidge, H.M., McKinley, R.L., 1996.  
317 Neutropenia with a probable hereditary basis in Border Collies. *N.Z. Vet. J.* 44,  
318 67–72.
- 319 Bauer, T.R. Jr., Gu, Y.C., Tuschong, L.M., Burkholder, T., Bacher, J.D., Starost, M.F.,  
320 Donahue, R.E., Sokolic, R.A., Hickstein, D.D., 2005. Nonmyeloablative hematopoietic  
321 stem cell transplantation corrects the disease phenotype in the canine model of  
322 leukocyte adhesion deficiency. *Exp. Hematol.* 33, 706-712.
- 323 Bauer, T.R., Jr., Hai, M., Tuschong, L.M., Burkholder, T.H., Gu, Y.C., Sokolic, R.A.,  
324 Ferguson, C., Dunbar, C.E., Hickstein, D.D., 2006. Correction of the disease phenotype  
325 in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene  
326 therapy. *Blood* 108, 3313-3320.
- 327 Bauer, T.R., Jr., Allen, J.M., Hai, M., Tuschong, L.M., Khan, I.F., Olson, E.M., Adler,  
328 R.L., Burkholder, T.H., Gu, Y.C., Russell, D.W., Hickstein, D.D., 2007. Successful  
329 treatment of canine leukocyte adhesion deficiency by foamy virus vectors. *Nat. Med.*  
330 14, 93-97.
- 331 Elhasid, R., Rowe, J.M., 2010. Hematopoietic stem cell transplantation in neutrophil  
332 disorders: severe congenital neutropenia, leukocyte adhesion deficiency and chronic  
333 granulomatous disease. *Clin. Rev. Allergy Immunol.* 38, 61-67.
- 334 Kijas, J.M., Bauer, T.R. Jr., Gäfvert, S., Marklund, S., Trowald-Wigh, G., Johannisson,  
335 A., Hedhammar, A., Binns, M., Juneja, R.K., Hickstein, D.D., Andersson, L., 1999. A  
336 missense mutation in the beta-2 integrin gene (ITGB2) causes canine leukocyte  
337 adhesion deficiency. *Genomics* 61, 101–107.

- 338 Kobayashi, S., Sato, R., Inanami, O., Yamamori, T., Yamato, O., Maede, Y., Sato, J.,  
339 Kuwabara, M. and Naito, Y., 2005. Reduction of concanavalin A-induced expression  
340 of interferon- $\gamma$  by bovine lactoferrin in feline peripheral blood mononuclear cells. *Vet.*  
341 *Immunol. Immunopathol.* 105, 75-84.
- 342 Kobayashi, S., Sato, R., Aoki, T., Omoe, K., Inanami, O., Hankanga, C., Yamada, Y.,  
343 Tomizawa, N., Yasuda, J. and Sasaki, J., 2008. Effect of bovine lactoferrin on  
344 functions of activated feline peripheral blood mononuclear cells during chronic feline  
345 immunodeficiency virus infection. *J. Vet. Med. Sci.* 70, 429-435.
- 346 Kobayashi, S., Sato, R., Abe, Y., Inanami, O., Yasui, H., Omoe, K., Yasuda, J.,  
347 Hankanga, C., Oda, S., Sasaki, J., 2009. Canine neutrophil dysfunction caused by  
348 downregulation of beta2-integrin expression without mutation. *Vet. Immunol.*  
349 *Immunopathol.* 130, 187-196.
- 350 Lönnerdal, B., Iyer, S., 1995. Lactoferrin: molecular structure and biological function.  
351 *Annu. Rev. Nutr.* 15, 93-110.
- 352 Mócsai, A., Zhou, M., Meng, F., Tybulewicz, V.L., Lowell, C.A., 2002. Syk is required  
353 for integrin signaling in neutrophils. *Immunity* 16, 547-558.
- 354 Nagahata, H., Nochi, H., Tamoto, K., Taniyama, H., Noda, H., Morita, M., Kanamaki,  
355 M., Kociba, G.J., 1993. Bovine leukocyte adhesion deficiency in Holstein cattle. *Can. J.*  
356 *Vet. Res.* 57, 255-261.
- 357 Neuman, E., Huleatt, J.W., Jack, R.M., 1990. Granulocyte-macrophage  
358 colony-stimulating factor increases synthesis and expression of CR1 and CR3 by  
359 human peripheral blood neutrophils. *J. Immunol.* 145, 3325-3332.



- 360 Nielsen, C.H., Antonsen, S., Matthiesen, S.H., Leslie, R.G., 1997. The roles of  
361 complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) in the  
362 regulation of the immune complex-elicited respiratory burst of polymorphonuclear  
363 leukocytes in whole blood. *Eur. J. Immunol.* 27, 2914-2919.
- 364 Noti, J.D., Reinemann, B.C., Johnson, A.K., 2001. The leukocyte integrins are regulated  
365 by transcriptional and post-transcriptional mechanisms in a leukemic cell that  
366 overexpresses protein kinase C-zeta. *Int. J. Oncol.* 19, 1311-1318.
- 367 Richter, J., Ng-Sikorski, J., Olsson, I., Andersson, T., 1990. Tumor necrosis  
368 factor-induced degranulation in adherent human neutrophils is dependent on  
369 CD11b/CD18-integrin-triggered oscillations of cytosolic free Ca<sup>2+</sup>. *Proc. Natl. Acad.*  
370 *Sci. U. S. A.* 87, 9472-9476.
- 371 Roy-Ghanta, S., Orange, J.S., 2010. Use of cytokine therapy in primary  
372 immunodeficiency. *Clin. Rev. Allergy Immunol.* 38, 39-53.
- 373 Sato, R., Inanami, O., Tanaka, Y., Takase, M., Naito, Y., 1996. Oral administration of  
374 bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency  
375 virus (FIV)-positive and FIV-negative cats. *Am. J. Vet. Res.* 57, 1443-1446.
- 376 Seger, R.A., 2010. Advances in the diagnosis and treatment of chronic granulomatous  
377 disease. *Curr. Opin. Hematol.* (Epub ahead of print)
- 378 Spik, G., Legrand, D., Leveugle, B., Mazurier, J., Mikogami, T., Montreuil, J., Pierce,  
379 A., Rochard, E., 1994. Characterization of two kinds of lactotransferrin (lactoferrin)  
380 receptors on different target cells. *Adv. Exp. Med. Biol.* 357, 13-19.

- 381 Suchard, S.J., Boxer, L.A., 1994. Exocytosis of a subpopulation of specific granules  
382 coincides with H<sub>2</sub>O<sub>2</sub> production in adherent human neutrophils. *J. Immunol.* 152,  
383 290-300.
- 384 Takeuchi, T., Kitagawa, H., Harada, E., 2004. Evidence of lactoferrin transportation into  
385 blood circulation from intestine via lymphatic pathway in adult rats. *Exp. Physiol.* 89,  
386 263-270.
- 387 Ward, P.P., Uribe-Luna, S., Conneely, O.M., 2002. Lactoferrin and host defense.  
388 *Biochem. Cell Biol.* 80, 95-102.
- 389 Ward, P.P., Paz, E., Conneely, O.M., 2005. Multifunctional roles of lactoferrin: a critical  
390 overview. *Cell Mol. Life Sci.* 62, 2540-2548.
- 391 Ward, P.P., Mendoza-Meneses, M., Park, P.W., Conneely, O.M., 2008.  
392 Stimulus-dependent impairment of the neutrophil oxidative burst response in  
393 lactoferrin-deficient mice. *Am. J. Pathol.* 172, 1019-1029.
- 394 Yamada, Y., Sato, R., Kobayashi, S., Hankaga, C., Inanami, O., Kuwabara, M.,  
395 Momota, Y., Tomizawa, N. and Yasuda, J., 2008. The antiproliferative effect of bovine  
396 lactoferrin on canine mammary gland tumor cells. *J. Vet. Med. Sci.* 70, 443-448.
- 397 Yamauchi, K., Wakabayashi, H., Hashimoto, S., Teraguchi, S., Hayasawa, H., Tomita,  
398 M., 1998. Effects of orally administered bovine lactoferrin on the immune system of  
399 healthy volunteers. *Adv. Exp. Med. Biol.* 443, 261-265.
- 400 Yamauchi, K., Toida, T., Nishimura, S., Nagano, E., Kusuoka, O., Teraguchi, S.,  
401 Hayasawa, H., Shimamura, S., Tomita, M., 2000. 13-Week oral repeated  
402 administration toxicity study of bovine lactoferrin in rats. *Food Chem. Toxicol.* 38,  
403 503-512.
- 404

404 **Figure captions**

405

406 **Fig. 1.** The effects of oral administration of bovine lactoferrin on transcript level of  
407 neutrophil adhesion molecules and surface expression in the affected dog. Mean values  
408 and min-max range are shown in controls and the affected dog. (A) The transcript levels  
409 of CD11b and  $\beta$ 2-integrin before (Pre), 54 days and 140 days after oral administration  
410 of bovine lactoferrin were measured by real-time RT-PCR. The administration was  
411 resumed on day 140 after 14 days of suspension due to his owner's reasons. The results  
412 were expressed as a ratio of CD11b or  $\beta$ 2-integrin to  $\beta$ -actin. (B) Surface expression of  
413 CD11b and CD18 on neutrophils was quantified by a whole blood flow cytometric assay.  
414 The results were expressed as mean fluorescence intensity (MFI).

415

416 **Fig. 2.** The effect of oral administration of bovine lactoferrin on OZ-stimulated  
417 superoxide production in the affected dog. Superoxide production in the affected dog  
418 was measured by chemiluminescence before ( $\circ$ ), 14 ( $\bullet$ ) and 94 ( $\bullet$ ) days after oral  
419 treatment with bovine lactoferrin. The result of healthy controls is expressed as the  
420 mean of five experiments measured ( $\square$ ).

421

422 **Fig. 3.** The effects of oral administration of bovine lactoferrin on neutrophil adherence  
423 and phagocytic activity in the affected dog. The result of healthy controls ( $\square$ ) and the  
424 affected dog ( $\blacktriangle$ ) is expressed as the mean and min-max range. The administration was  
425 resumed on day 140 after 14 days of suspension due to his owner's reasons. (A)  
426 Neutrophil adherence was measured by the nylon fiber adherence assay. The results

427 were expressed as percentage of neutrophil adherence to nylon fibers. (B) Non-specific  
428 phagocytic activity of neutrophils was measured by a whole blood flow cytometric  
429 assay using non-opsonized fluorescent microspheres. Phagocytic activity expressed as  
430 percentage of the total neutrophil population ingesting fluorescent microspheres.

Accepted Manuscript




Fig 1. Kobayashi et al.




Fig 2. Kobayashi et al.





Fig 3. Kobayashi et al.